Palisade Bio (NASDAQ:PALI) Director Robert Jr. Baltera Purchases 50,000 Shares of Company Stock

Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) Director Robert Baltera acquired 50,000 shares of the company’s stock in a transaction dated Tuesday, November 17th. The shares were bought at an average cost of $1.01 per share, with a total value of $50,500.00. Following the completion of the acquisition, the director directly owned 511,904 shares in the company, valued at $517,023.04. The trade was a 10.82% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Palisade Bio Price Performance

Shares of PALI opened at $0.93 on Friday. The firm has a market cap of $165.91 million, a P/E ratio of -1.93 and a beta of 1.61. The stock has a 50 day simple moving average of $1.39 and a two-hundred day simple moving average of $1.80. Palisade Bio, Inc. has a 1 year low of $0.92 and a 1 year high of $2.85.

Palisade Bio (NASDAQ:PALI – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). On average, equities analysts anticipate that Palisade Bio, Inc. will post -0.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Oppenheimer reiterated an “outperform” rating on shares of Palisade Bio in a research report on Wednesday, October 21st. Raymond James Financial started coverage on Palisade Bio in a research note on Thursday, October 8th. They set an “outperform” rating and a $6.00 price objective on the stock. Wall Street Zen downgraded Palisade Bio from a “sell” rating to a “strong sell” rating in a report on Saturday, November 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a report on Monday, October 12th. Finally, HC Wainwright lowered their target price on Palisade Bio to $5.00 and set a “buy” rating for the company in a research note on Wednesday, November 11th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Palisade Bio currently has a consensus rating of “Buy” and a consensus price target of $9.00.

Check Out Our Latest Analysis on PALI

Hedge Funds Weigh In On Palisade Bio

Several large investors have recently made changes to their positions in PALI. Legal & General Group Plc bought a new stake in shares of Palisade Bio in the 2nd quarter worth approximately $30,000. CTC Alternative Strategies Ltd. bought a new position in Palisade Bio during the 1st quarter valued at approximately $31,000. GSA Capital Partners LLP bought a new position in Palisade Bio during the 2nd quarter valued at approximately $54,000. Two Sigma Securities LLC bought a new position in Palisade Bio during the 2nd quarter valued at approximately $57,000. Finally, Susquehanna International Group LLP purchased a new position in Palisade Bio during the second quarter valued at $65,000. 11.79% of the stock is currently owned by hedge funds and other institutional investors.

About Palisade Bio

(Get Free Report)

Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.

Read More

Insider Buying and Selling by Quarter for Palisade Bio (NASDAQ:PALI)

Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.